Adjuvant compositions

Details Adjuvant compositions Adjuvant compositions

2002-10-03

2009-06-23

Chen, Stacy B (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S218100, C424S278100

Reexamination Certificate

active

07550145

ABSTRACT:
Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.

REFERENCES:
patent: 3906092 (1975-09-01), Hilleman et al.
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5712257 (1998-01-01), Carter
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5906980 (1999-05-01), Carter
patent: 6086901 (2000-07-01), O'Hagan et al.
patent: 6150087 (2000-11-01), Chien
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6299884 (2001-10-01), Van Nest et al.
patent: 6306405 (2001-10-01), O'Hagan et al.
patent: 6451325 (2002-09-01), Van Nest et al.
patent: 6458370 (2002-10-01), O'Hagan et al.
patent: 6855492 (2005-02-01), O'Hagan et al.
patent: 6861410 (2005-03-01), Ott et al.
patent: 6884435 (2005-04-01), O'Hagan et al.
patent: 0 991 403 (2003-02-01), None
patent: 1 156 781 (2005-08-01), None
patent: WO 90/14837 (1990-12-01), None
patent: WO 98/33487 (1998-08-01), None
patent: WO 99/02132 (1999-01-01), None
patent: WO 99/30737 (1999-06-01), None
patent: WO 00/06123 (2000-02-01), None
patent: WO 00/15768 (2000-03-01), None
patent: WO 00/67787 (2000-05-01), None
patent: WO 00/50006 (2000-08-01), None
patent: WO 01/36599 (2001-05-01), None
Pizza et al. Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing, Science, Mar. 10, 2000, vol. 287, pp. 1816-1820.
Le Bon et al., “Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo,”Immunity14:461-470, 2001.
Majde, “Viral double-stranded RNA, cytokines, and the flu,”J. Interferon and Cytokine Research20:259-272, 2000.
Ott et al., “MF59—Design and evaluation of a safe and potent adjuvant for human vaccines,” inVaccine Design: The Subunit and Adjuvant Approach(Powell, M.F. and Newman, M.J. eds.) Plenum Press, New York, 1995, pp. 277-296.
Singh et al., “Cationic microparticles: a potent delivery system for DNA vaccines,”PNAS97(2):811-816, 2000.
Tazulakhova et al., “Russian experience in screening, analysis, and clinical application of novel interferon inducers,”J. Interferon and Cytokine Research21:65-73, 2001.
Cella, et al., “Maturation, Activation, and Protection of Dendritic Cells Induced by Double-Stranded RNA,”J Exp Med189(5):821-829 (1999).
Dupuis, et al., “Dendritic Cells Internalize Vaccine Adjuvant After Intramuscular Injection,”Cellular Immunology186:18-27 (1998).
McCluskie, et al., CpG DNA is an Effective Oral Adjutant to Protein Antigens in Mice,Vaccine19:950-957 (2001).
Moss, et al., “In Vitro Immune Function After Vaccination with an Inactivated gp 120 Depleted HIV-1 Antigen with Immunostimulatory Oligonucleotides,”Vaccine18:1081-1087 (2000).
Moss, et al., “Human Immunodeficiency Virus (HIV)-Specific Immune Responses are Generated with the Simultaneous Vaccination of gp 120-Depleted Whole-Killed HIV-1 Immunogen with Cytosine-Phosphorothioate-Guanine Dinucleotide Immunostimulatory Sequence of DNA,”J Hum Virol4:39-43 (2001).
O'Hagan, et al., “Synergistic Adjuvant Activity of Immunostimulatory DNA Oil/Water Emulsions for Immunization with HIV p55 Gag Antigen,”Vaccine20:3389-3398 (2002).
O'Hagan, et al., “Microparticles in MF59, A Potent Adjuvant Combination for a Recombinant Protein Vaccine Against HIV-1,”Vaccine18:1793-1801 (2000).
Parkin, et al., “An Overview of the Immune System,”The Lancet357:1777-1789 (2001).
Singh, et al., “Advances in Vaccine Adjuvants,”Nature Biotechnol17(11):1075-1081 (1999).

Affiliated with

Also associated with

Rating

Adjuvant compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adjuvant compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4097806